OmniTier

OmniTier

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2018 and headquartered in San Francisco, OmniTier is a private computational biology company focused on delivering affordable, on-premise genomic analysis solutions. Its core technology leverages memory-centric computing and AI to accelerate and improve the accuracy of variant calling and interpretation, targeting clinical diagnostics and research. The company offers standalone appliances, such as the CompStor series, which aim to reduce analysis costs and time while maintaining data security and control for its customers.

Rare DiseasesGenetic Disorders

Technology Platform

Memory-centric high-performance computing software stack integrated with AI-powered workflows for genomic secondary and tertiary analysis, deployed on standalone on-premise appliances.

Opportunities

The growing emphasis on data privacy and sovereignty in clinical genomics creates a strong demand for secure, on-premise analysis solutions.
The rapid expansion of population genomics and large-scale screening programs presents a massive market for high-volume, low-cost-per-sample analysis platforms.

Risk Factors

Intense competition from dominant cloud providers and established bioinformatics software companies poses a significant market penetration challenge.
The company's hardware-dependent model faces risks from supply chain issues, long sales cycles, and the need for continuous capital investment to fund growth.

Competitive Landscape

OmniTier competes against large cloud infrastructure providers (AWS, Google Cloud, Microsoft Azure), specialized bioinformatics SaaS platforms (DNAnexus, Seven Bridges, Pierian), and the analysis tools bundled by sequencing instrument companies (Illumina DRAGEN, PacBio). Its key differentiation is the integrated on-premise appliance offering lower operational costs and enhanced data control.